Drug Profile

Candida antigen - Nielson Biosciences

Alternative Names: Candida albicans antigen - Nielson Biosciences; Candida albicans skin test antigen - Nielson Biosciences; Candin

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nielsen BioSciences
Developer Janssen Research & Development; Nielsen BioSciences
Class Antigens; Diagnostic agents; Skin disorder therapies; Yeasts
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hypersensitivity
Phase III Warts

Most Recent Events

26 Feb 2025 Nielsen plans regulatory submissions for Warts (Intradermal) in USA
26 Feb 2025 Nielsen Biosciences completes enrolment in phase-III trial for Warts in USA (NCT05889845)
07 Mar 2024 Maruho plans to commercialise CANDIN in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com